Nong Yang
No.87 Xiangya Road
Changsha, 410008, China
Changsha, 410008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 196 publications
Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial.
Journal: JAMA surgery
Published: July 15, 2026
Expert consensus on the detection and clinical application of tumor mutational burden.
Journal: Cancer biology & medicine
Published: February 18, 2026
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.
Journal: Cell reports. Medicine
Published: January 07, 2026
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.
Journal: Cell reports. Medicine
Published: October 21, 2025
A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of NHWD-870 HCl in Patients with Lymphoma and Other Advanced Solid Tumors.
Journal: Recent patents on anti-cancer drug discovery
Published: October 12, 2025
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Journal: Nature communications
Published: September 13, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 22, 2025
Last Updated: 09/26/2026